William J. Tremaine

TL;DR: Subgroups of IBD patients—those with PSC, severe long-standing disease, and exposure to x-ray—were at greater risk of colorectal neoplasia, and the protective effect of close follow-up, colonoscopy, and treatment with 5-aminosalicylates was questionable.

TL;DR: The increased frequency of perinuclear antineutrophil cytoplasmic antibodies in treatment-resistant left-sided ulcerative colitis suggests a possible association between these antibodies and relative resistance to medical therapy in patients with ulceratives colitis.

TL;DR: Although the number of patients in this study was relatively small, Asacol 3.2 g/day appears to be safe and effective treatment for mildly to moderately active Crohn's colitis and ileocolitis as compared with placebo, and this regimen is an option for treatment of patients who fail or are intolerant of sulfasalazine.

TL;DR: This population‐based cohort study from Olmsted County, Minnesota did not confirm an increased risk of cancer related to fLGD, whereas 22% of patients with ALMs in areas of IBD developed f LGD or DALMs, and primary sclerosing cholangitis and dysplasia located proximal to the splenic flexure were significantly associated with risk for recurrence/progression of dysplia.

TL;DR: The preliminary results suggest that cyclooxygenase-2 inhibitors may be safe and beneficial in most patients with IBD, and a placebo-controlled trial to confirm these preliminary observations is needed.